Observational studyAntimicrobial agents and chemotherapy2021
Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic Fibrosis.
Observational study in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04335370 (Pharmacokinetics of Polymyxin B in Adult Patients With Cystic Fibrosis), which is not on this map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacokinetics of Polymyxin B in Adult Patients With Cystic Fibrosis
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- A Systematic Review of Pharmacokinetic Studies of Colistin and Polymyxin B in Adult Populations.Clinical pharmacokinetics · 2025Pooled it
- Pharmacokinetics of polymyxin B in different populations: a systematic review.European journal of clinical pharmacology · 2024Pooled it
- Comparative Genomics of Paenibacillus Secondary Metabolism: Unveiling the Putative Biosynthetic Gene Cluster for Paenialvins in Paenibacillus Alvei Strain 32.Probiotics and antimicrobial proteins · 2026Article
- Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling.CPT: pharmacometrics & systems pharmacology · 2026Article
- The pharmacodynamics of polymyxin B in Acinetobacter baumannii in murine thigh and lung infection models.The Journal of antimicrobial chemotherapy · 2026Article
- Pharmacokinetics of polymyxin drugs in special populations.Frontiers in pharmacology · 2026Review
- Can the two-point method based on peak and trough concentrations accurately estimate the area under the curve of polymyxin B? A Monte Carlo simulation study.Frontiers in pharmacology · 2026Article
- A Multi-Center Study of Population Pharmacokinetics of Polymyxin B in Critically Ill Patients.Drug design, development and therapy · 2026Article
- Population pharmacokinetics of polymyxin B in critically ill patients with carbapenem-resistant organisms infections: insights from steady-state trough and peak plasma concentration.Frontiers in pharmacology · 2025Article
- A systematic evaluation of population pharmacokinetic models for polymyxin B in patients with liver and/or kidney dysfunction.Journal of pharmacokinetics and pharmacodynamics · 2024Article
- How can polymyxin B be dosed based on current pharmacokinetic knowledge?European journal of clinical pharmacology · 2024Article
- Comparative pharmacokinetics of polymyxin B in critically ill elderly patients with extensively drug-resistant gram-negative bacteria infections.Frontiers in pharmacology · 2024Article
- Population pharmacokinetics of polymyxin B: a systematic review.Annals of translational medicine · 2022Review
- Effects of Aerosol Inhalation Combined with Intravenous Drip of Polymyxin B on Bacterial Clearance, Symptoms Improvement, and Serum Infection Indexes in Patients with Pneumonia Induced by Multidrug-Resistant Gram-Negative Bacteria.Emergency medicine international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal polymyxin B dosage needed to achieve an efficacy target of 50 to 100 mg · h/liter when treating multidrug-resistant bacterial infections in adult cystic fibrosis (CF) patients is unclear. The pharmacokinetics of intravenous polymyxin B were evaluated to better inform dosing. This was a prospective, observational pharmacokinetic (PK) study of nine CF adults receiving intravenous polymyxin B as part of usual clinical care. Doses preceding PK sampling ranged from 50 to 100 mg every 12 h. Five PK samples were collected following the fourth or fifth dose and concentrations of polymyxin subcomponents B1 and B2 were quantified using liquid chromatography mass spectrometry (LC-MS). Population PK (NONMEM software) analysis was performed using pooled polymyxin B1+B2 concentrations. Participants were Caucasian, predominantly male, with mean age and weight of 31 years (range 21 to 57 years) and 58.0 kg (range 38.3 to 70.4 kg), respectively. A 1-compartment zero-order infusion and linear elimination model adequately described the data with estimated clearance and volume of distribution being 2.09 liters/h and 12.7 liters, respectively, corresponding to a 4.1 h mean half-life (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.